Evogene Subsidiary Biomica Licenses Cancer Therapeutic BMC128 to Lishan Biotech

summarizeSummary

Evogene's subsidiary, Biomica, entered an exclusive worldwide licensing agreement with Shanghai Lishan Biopharmaceuticals for BMC128, a microbiome-based therapeutic for cancer, which includes milestone payments and royalties.

check_boxKey Events

• Exclusive Global Licensing Agreement

  Evogene's subsidiary, Biomica Ltd., granted Shanghai Lishan Biopharmaceuticals Co., Ltd. exclusive worldwide rights to develop, manufacture, and commercialize BMC128.

• Microbiome-Based Cancer Therapeutic

  BMC128 is a first-in-class microbiome-based therapeutic designed to enhance anti-tumor immune activity, currently completing a Phase 1 clinical study with promising early results in renal cell carcinoma and non-small cell lung cancer.

• Potential Future Revenue Streams

  Biomica is eligible to receive development milestone payments, sales milestone payments, and royalties from Lishan Biotech's future sales of BMC128.

• Advancement to Phase 2 Clinical Study

  Lishan Biotech plans to advance BMC128 into a Phase 2 clinical study and pursue regulatory filings in China and the United States.

auto_awesomeAnalysis

Evogene's subsidiary, Biomica, has secured a significant global licensing agreement for its microbiome-based therapeutic, BMC128. This partnership with Shanghai Lishan Biopharmaceuticals validates Biomica's research and development capabilities, particularly for a therapeutic that has shown promising early clinical results in Phase 1 studies for renal and lung cancer. For a company of Evogene's size, this agreement represents a crucial non-dilutive funding pathway through potential development milestones and future sales royalties, significantly de-risking the program's advancement and providing a clear path to commercialization without direct financial burden on Biomica. The commitment by Lishan Biotech to advance BMC128 into Phase 2 clinical studies and pursue regulatory filings in major markets like China and the U.S. underscores the potential impact of this therapeutic.